Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Phase II Study of RC1416 Injection in COPD

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of RC1416 injection in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Participants needed: 180
Trial details
Phase: Phase 2Age: 40-85Biological sex: AllType: InterventionalSponsor: Nanjing RegeneCore Biotech Co., Ltd.Updated: Apr 17, 2026Locations: 41
Eligibility criteria

Aged 40 to 85 years (inclusive) at the time of signing the informed consent form... [+8]

A current diagnosis of asthma or a history of asthma. [+8]

Read more
Status: Not yet recruiting

Phase II Trial of RC1416 Injection in Asthma

This study is a phase II study of RC1416 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of RC1416 in subjects with severe uncontrolled asthma.

Participants needed: 195
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Nanjing RegeneCore Biotech Co., Ltd.Updated: Feb 11, 2026Locations: 45
Eligibility criteria

Male or female aged 18 and 75 years. [+6]

Individuals with a known history of allergy to the investigational product or it... [+11]

Read more
Status: Recruiting

This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.

This study is a first-in-human (FIH) study which is required to understand the safety, tolerability, pharmacokinetics and preliminary efficacy of RJK-RT2831 injection in patients with hematologic malignancies

Participants needed: 71
Trial details
Phase: Phase 1Age: 18-74Biological sex: AllType: InterventionalSponsor: Nanjing RegeneCore Biotech Co., Ltd.Updated: Jan 30, 2026Locations: 16
Eligibility criteria

1. A male or female aged ≥ 18 and <75 years old. [+11]

1. APL is suspected or confirmed based on morphology, immunophenotyping, molecul... [+32]

Read more